**AUB KQ1 Evidence Table (Reference ID #871)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author**:Bonnar and Sheppard, 1996**Country**:Ireland**Enrollment** **period**: NR**Intervention** **setting**: University department of OB-GYN**Funding**:Health Research Board of Ireland and Pharmacia, Sweden**Author industry relationship disclosures:**None**Study Design:** RCT**Blinding**: None | **Intervention/ Comparator:**Tranexamic acid 1 g six hourly; mefenamic acid 500 mg eight hourly; ethamsylate 500 mg six hourlyAll treatments taken for five days from day 1 of bleeding for three cycles**Groups:****G1:** Tranexamic acid**G2:** Mefenamic acid**G3:** Ethamsylate**Followup:**3 cycles | **Inclusion criteria:** * Aged 35 to 46 years
* Complaint of regular heavy menstrual bleeding

Mean menstrual loss >80 ml measured over three consecutive menstrual periods before treatment**Exclusion criteria:** Organic causes of menorrhagia excluded by hysteroscopy, endometrial biopsy, cervical smear test 3 to 12 months before enrollmentHistory of renal or hepatic impairmentPrevious thromboembolic diseaseInflammatory bowel diseasePeptic or intestinal ulcerationCoagulation or fibrinolytic disorders**N at enrollment:** **G1:** 27**G2:** 25**G3:** 29**N at followup:** **G1:** 26**G2:** 23**G3:** 27**Age, mean years ± SD:****G1:** 40 ± 5**G2:** 38 ± 8**G3:** 37 ± 8**BMI:**NR**Height, mean cm ± SD:****G1:** 160 ± 6**G2:** 161 ± 6**G3:** 164 ± 7**Weight, mean kg ± SD:****G1:** 66 ± 10**G2:** 66 ± 12**G3:** 64 ± 9**Parity:**NR**Race/ethnicity:**NR | **Bleeding:**MBL measured by alkaline hematin method during 3 cycles pretreatment, mean ml:**G1:** 164**G2:** 186**G3:** 170MBL duration, mean days ± SD:**G1:** 5.5 ± 1.4**G2:** 5.8 ± 1.3**G3:** 5.7 ± 1.1Sanitary towels, mean ± SD:**G1:** 23 ± 7.0**G2:** 25 ± 7.0**G3:** 25 ± 9.0 | **Bleeding:**MBL measured by alkaline hematin method during 3 treatment cycles, mean ml:**G1:** 75**G2:** 148**G3:** 175MBL change, n (%):Less:**G1:** 18 (69)**G2:** 13 (57)**G3:** 12 (44)Same:**G1:** 4 (15)**G2:** 5 (22)**G3:** 5 (19)Greater:**G1:** 4 (15)**G2:** 4 (17)**G3:** 8 (30)Dysmenorrhea change, n (%):Better:**G1:** 5 (19)**G2:** 3 (13)**G3:** 1 (4)Same:**G1:** 14 (54)**G2:** 11 (48)**G3:** 19 (70)Worse:**G1:** 7 (27)**G2:** 8 (35)**G3:** 4 (15)MBL duration, mean days ± SD:**G1:** 4.9 ± 1.8**G2:** 5.3 ± 1.3**G3:** 5.7 ± 2.0Sanitary towels, mean ± SD, p value:**G1:** 20 ± 6.0, p<0.01**G2:** 23 ± 9.0, p<0.05 **G3:** 25 ± 9.0**G1 vs. BL:** p<0.01**G2 vs. BL:** p<0.05 **G3 vs. BL:** p=NS**Quality of life:**NR**Pain:**NR**Sexual function:**NR**Patient satisfaction:**Wish to continue treatment at end of study, n (%):**G1:** 20 (77)**G2:** 17 (74)**G3:** NR **Fertility:**NR**Time to conception:**NR**Additional interventions:**NR**Adverse events:**Withdrawal,a n: **G1:** 4**G2:** 3**G3:** 11 Withdrawal due to unwanted event such as nausea, headache or dizziness, n: **G1:** 3**G2:** 1**G3:** 4 | **Overall quality:**Poor**Risk of bias:** Randomization: LowAllocation concealment:UnclearSelective reporting:UnclearBlinding patients/personnel:HighBlinding outcome assessment:HighIncomplete outcome reporting:LowOther:Low |

**Table Notes**: a Reasons for withdrawal: poor efficacy (G3: n=5; G2: n=1); unwanted event such as nausea, headache and dizziness (G1: n=3; G2: n=1; G3: n=4).